Quantum Leap Healthcare Collaborative
search

I-SPY in the News

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.

I-SPY updates breast cancer subtypes with response-predictive biomarkers generated across 10 therapies

Media Contact:

Karyn DiGiorgio
Quantum Leap Healthcare Collaborative
karyn.digiorgio@quantumleaphealth.org